Navigation Links
Nventa Appoints John Varian to Board of Directors
Date:5/7/2008

- New Member Complements Board With Significant Financial and Operational

Expertise -

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today the appointment of John Varian to the company's board of directors. Mr. Varian currently serves as the chief operating officer and chief financial officer of Aryx Therapeutics, a pharmaceutical company focused on the discovery and development of oral therapeutics for chronic disease.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

"We are very pleased to welcome John to Nventa's board," commented Gregory M. McKee, president and chief executive officer at Nventa. "His extensive experience in helping companies establish strategic direction, raise venture and public capital, and negotiate successful alliances and acquisitions should be extremely beneficial to Nventa as it grows internally and continues its path to commercializing its first product."

Prior to joining Aryx Therapeutics, Mr. Varian was chief financial officer of Genset S.A., where he was a key member of the team negotiating the company's sale to Serono S.A. in 2002. From October 1998 to April 2000, Mr. Varian served as senior vice president, finance and administration of Elan Pharmaceuticals, Inc., joining the company as part of its acquisition of Neurex Corporation. Prior to the acquisition, he served as Neurex Corporation's chief financial officer from June 1997 until October 1998. Mr. Varian is a founding member of the Bay Area Bioscience Center and a former chairman of the Association of Bioscience Financial Officers International Conference.

"I am proud to join the board at Nventa Biopharmaceuticals, a truly innovative company that is working to bring much needed therapeutic options to patients affected by HPV-related diseases," stated Mr.
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
2. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
3. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventas CEO to present at two upcoming investor conferences
6. Nventa announces publication of HspE7 data
7. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
8. Kendle Appoints Patricia Williams Vice President, Commercial Operations
9. Biomoda Appoints Three Business Leaders to Board of Directors
10. Shengtai Pharmaceutical, Inc. Appoints New CFO
11. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015 People with a common form ... significant and sometimes profound improvements in their hearing and ... to a new multicenter study led by specialists at ... described online ahead of print in the journal The Laryngoscope ... clinics in the United States ...
(Date:7/28/2015)... ... , ... VetStem Biopharma will be offering weekly private guided tours of our ... , The tour and course will be given every Wednesday at 6pm to local ... Staff members are welcome to attend with their veterinarian as well. Participants will be ...
(Date:7/28/2015)... , July 28, 2015 BioStructures, ... it has hit a milestone of 4,000 implantations ... FDA 510(k) cleared in early 2014 as a ... posterolateral spine fusion procedures.  This is a distinguished ... less than 6% of new synthetic products have ...
(Date:7/28/2015)... 2015  Faced with increasing challenges such as ... than symptomatic, the global healthcare industry today is ... of curing or significantly changing the course of ... towards regenerative medicine as a viable alternative. ... human health with the potential to resolve unmet ...
Breaking Biology Technology:Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Revolutionary Bone Graft Exceeds Expectations 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5
... on St. Patrick,s Day. It,s been used to find latent ... University have used it to examine the thinnest material in ... and Jiaxing Huang, assistant professor of materials science and engineering ... his research group have used the dye to create a ...
... , , BOTHELL, Wash., Dec. 23 BioLife Solutions, Inc. ... of biopreservation tools for cells, tissues, and organs, today announced ... and GMP production facility in Bothell, Washington by BSI Group ... international standard for quality systems supporting the design, development, and ...
... 21, 2009 Waukesha Electric Systems, SuperPower, University of Houston, ... partnering in a $10.7 million smart grid demonstration project ... Chu on November 24. The funds will be used ... boost the reliability of the nation,s power grid. ...
Cached Biology Technology:An easy way to see the world's thinnest material 2BioLife Solutions Achieves ISO 13485 Quality Management Systems Certification 2BioLife Solutions Achieves ISO 13485 Quality Management Systems Certification 3Waukesha Electric partners with SuperPower and UH to build fault current limiting superconducting transformer for Dept. of Energy 2Waukesha Electric partners with SuperPower and UH to build fault current limiting superconducting transformer for Dept. of Energy 3
(Date:6/26/2015)... SPRINGVILLE, Utah , June 26, 2015 ATL ... assemblies and devices with specialties in single use solutions, headquartered ... acquisition of MedConx, Inc. (a California ... , and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing ...
(Date:6/24/2015)... YORK , June 24, 2015 The ... rate. The major drivers for the market include growth ... number of new drug launches. Over the years, the ... increased. Between 2001 and 2010, the FDA approved 225 ... according to WIPO, Europe accounted ...
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... a statement on the chances and limits of using ... come to the conclusion that in quantitative terms, bioenergy ... sustainable energy sources in Germany at the present time ... area, is associated with higher greenhouse gas emissions and ...
... Sciences have teamed up to create a joint research institute ... effective and efficient ways to store energy is becoming increasingly ... electricity grids. The ability to store excess energy generated from ... People use a wide variety of technologies to store energy, ...
... July 26, 2012 Congenital hypothyroidism is thyroid hormone ... to neurocognitive impairments in infants and children. Although ... daily during pregnancy for normal fetal thyroid hormone production ... 1,100 g to be the safe upper limit for ...
Cached Biology News:University of Leeds and Chinese Academy of Sciences join forces 2University of Leeds and Chinese Academy of Sciences join forces 3Study associates excess maternal iodine supplementation with congenital hypothyroidism in newborns 2
Human TSLP MAb (Clone 258136)...
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Human OSCAR MAb (Clone 259501)...
Human/Mouse G9a/EHMT2 MAb (Clone A8620A) Keywords: Eu-HMTase2...
Biology Products: